We are live on ! Find out more
UTMD icon

Utah Medical Products

117 hedge funds and large institutions have $118M invested in Utah Medical Products in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 33 increasing their positions, 50 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

0% more funds holding

Funds holding: 117117 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

2.09% less ownership

Funds ownership: 67.62%65.54% (-2.1%)

14% less capital invested

Capital invested by funds: $136M → $118M (-$18.9M)

34% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 50

Holders
117
Holders Change
Holders Change %
0%
% of All Funds
1.42%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
10
Increased
33
Reduced
50
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Two Sigma Advisers
51
Two Sigma Advisers
New York
$274K -$133K -2,300 -32%
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$234K -$48.9K -844 -17%
Wells Fargo
53
Wells Fargo
California
$231K +$103K +1,779 +76%
PIM
54
Penobscot Investment Management
Massachusetts
$224K
P
55
&Partners
Tennessee
$212K +$23K +396 +12%
MAM
56
Martingale Asset Management
Massachusetts
$208K -$174 -3 -0.1%
SEI Investments
57
SEI Investments
Pennsylvania
$206K +$1.62K +28 +0.8%
Russell Investments Group
58
Russell Investments Group
United Kingdom
$158K -$71.6K -1,236 -30%
SOW
59
State of Wyoming
Wyoming
$157K +$27.6K +476 +20%
Bank of America
60
Bank of America
North Carolina
$152K +$64.9K +1,120 +70%
MIM
61
MetLife Investment Management
New Jersey
$123K
JP Morgan Chase
62
JP Morgan Chase
New York
$84.2K -$2.09K -36 -2%
New York State Common Retirement Fund
63
New York State Common Retirement Fund
New York
$80K
Mirae Asset Global ETFs Holdings
64
Mirae Asset Global ETFs Holdings
Hong Kong
$78.5K -$1.1K -19 -1%
CCM
65
Copeland Capital Management
Pennsylvania
$55K
Carson Wealth (CWM LLC)
66
Carson Wealth (CWM LLC)
Nebraska
$54K -$21.6K -373 -28%
PFSRSONJ
67
Police & Firemen's Retirement System of New Jersey
New Jersey
$53.6K
BNP Paribas Financial Markets
68
BNP Paribas Financial Markets
France
$36.3K -$23.9K -412 -39%
PNC Financial Services Group
69
PNC Financial Services Group
Pennsylvania
$28.5K -$5.33K -92 -15%
GSWM
70
Golden State Wealth Management
California
$28K
VCM
71
Versant Capital Management
Arizona
$24.6K -$4.46K -77 -15%
US Bancorp
72
US Bancorp
Minnesota
$24.4K +$1.27K +22 +5%
MPWT
73
MassMutual Private Wealth & Trust
Connecticut
$20.9K -$1.22K -21 -5%
Jones Financial Companies
74
Jones Financial Companies
Missouri
$19.3K +$9.28K +160 +87%
PWPS
75
Pinnacle Wealth Planning Services
Ohio
$18.9K +$19.6K +338 New

UTMD Hedge Fund Activity: Q4 2025 in Review

117 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q4 2025, worth a combined $118M — down 14% from $136M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new UTMD positions and 9 closed out — a net gain of 1 holder — while 33 added to existing stakes and 50 trimmed.

The largest buyer was Brandes Investment Partners, adding an estimated $776K. The largest seller was Isthmus Partners, cutting an estimated $1.68M.

  • 117 institutional investors held Utah Medical Products (UTMD) as of Q4 2025, unchanged from Q3 2025.
  • Funds reported $118M of Utah Medical Products stock for Q4 2025, down 14% quarter-over-quarter.
  • 10 funds opened new Utah Medical Products positions in Q4 2025 and 9 closed out, a net change of +1 holder.
  • The largest Utah Medical Products buyer in Q4 2025 was Brandes Investment Partners, an estimated $776K added.
  • The largest Utah Medical Products seller in Q4 2025 was Isthmus Partners, an estimated $1.68M sold.

Based on aggregated 13F filings for Q4 2025.